Equinox Quantitative publishes differentiated, thesis-driven coverage of Indian equities — explicit price targets, scenario analysis, and falsifiable catalysts. No momentum chasing. No consensus anchoring.
An excellent company priced as a story stock: 34.6x FY27E earnings for 4.9% EPS growth, a durable MFN pricing cap on ~28% of revenue, and a 60x-priced Organon acquisition diluting quality.
A value trap at 13x: 0.8% revenue CAGR over FY23–FY26, ~16% IT Services margins, and a Nifty 50 exit forcing passive selling into October. Consensus's growth inflection has not arrived.
Priced for perfection at 73x: mid-single-digit reality meets a mid-twenties multiple. World-class franchise — Maggi, Nescafé, KitKat, 70%+ ROE — but EPS compounds at 10% while the market pays 73x.
| Date | Company / Note | Sector | Rating | Target | Implied |
|---|---|---|---|---|---|
| 8 Sep 2026 | Sun Pharmaceutical Industries — Initiation | Pharmaceuticals | UNDERWEIGHT | ₹1,500 | −21% |
| 28 Aug 2026 | Wipro Ltd — Bear Case | IT Services | UNDERWEIGHT | ₹155 | −11.9% |
| 28 Aug 2026 | Nestlé India Ltd — Initiation | Consumer Staples — Packaged Foods | UNDERWEIGHT | ₹1,150 | −20.6% |
| 28 Aug 2026 | Torrent Pharmaceuticals — JB Chemicals Synergies | Pharmaceuticals — Branded Generics | OVERWEIGHT | ₹5,800 | +16% |
| 27 Aug 2026 | BSE Ltd — Bull Thesis | Financial Exchanges | BUY | ₹4,400 | +32% |
| 27 Aug 2026 | BSE Ltd — Valuation Check | Financial Exchanges | UNDERWEIGHT | ₹2,400 | −28% |
Every coverage decision starts with the reported numbers — revenue quality, margin trajectory, cash conversion and balance-sheet direction — not with narratives.
Each note states the rating, the multiple it rests on, and the specific observable events that would prove it wrong. If a thesis can't be falsified, we don't publish it.
Every target comes with bear/base/bull scenarios and explicit reward-to-risk. We publish conviction levels and position-sizing guidance, not just calls.